Immatics Presents Clinical Activity of Two PRAME Therapies at 2026 ESMO Meeting
Immatics says it will present clinical activity of IMA402 and IMA203CD8 in advanced solid tumors in two oral presentations at the 2026 ESMO Annual Meeting.
Immatics says it will present clinical activity of IMA402 and IMA203CD8 in advanced solid tumors in two oral presentations at the 2026 ESMO Annual Meeting.